SEATTLE, WA / Marketwired / Feb 9, 2017
CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing Abattis Bioceuticals Inc. ( CSE : AT ) ( OTC PINK : ATTBF ) and the role the company’s subsidiary, Northern Vine Labs, and similar labs play in the burgeoning Canadian legal cannabis industry.
The Canadian cannabis industry could see $4.9 billion to $8.7 billion in annual sales after recreational legalization in enacted, according to Deloitte, with ancillary goods and services pushing that figure to between $12.7 billion and $22.6 billion. These figures have attracted a growing number of companies and investors to the lucrative market.
But, the industry’s rapid growth hasn’t come without growing pains. Two licensed producers (LP’s) voluntarily recalled hundreds of grams of dried marijuana in recent weeks after traces of controversial, banned pesticides were detected in their supplies. On Feb 7th, 2017, yet another Globe and Mail article highlighted the immediate need for testing and Health Canada is now preparing to introduce random testing on the licensed producers in an effort to clamp down on the problem. When asked why mandatory testing was not yet implemented for all LP’s, a Health Canada senior official stated he believed “there are only about three labs in Canada that could perform such testing, and there would be a backlog.”
Licensed producers looking to avoid issues with pesticides must seek out high-quality laboratories that run comprehensive testing on approved and banned pesticides. These labs should also be capable of running required tests on cannabis edibles and extracts designed to assess cannabinoid concentrations, bioavailability of capsules, and other aspects of the drugs. And of course, third party testing provides a greater level of transparency than in-house options.
Abattis Bioceuticals Inc.’s Northern Vine Labs subsidiary focuses on providing high-quality, independent testing for licensed producers, consumers, and others within Canada’s cannabis industry. With a Controlled Substance License (“CSL”), the company is one of just 18 approved laboratories in the country that offers product certification and quality assurance programs that incorporate best practices and procedures.
Please follow the link to read the full article: http://www.cannabisfn.com/abattis-addresses-key-shortcomings-in-canadas-cannabis-industry
Learn how to become a CFN Media featured company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company
Download the CFN Media iOS mobile app to access the world of cannabis from your smart phone: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer